The time-old THC/CBD balance of marijuana medication has been thrown a curveball. Enter the Panakeia strain and its high concentration of Cannabigerol, also known as CBG.
As the world’s first THC-free cannabis plant, Panekeia presents none of the psychoactive effects usually associated with cannabis treatment. Because of this, Panakeia has a significant advantage in the eyes of the law for cultivation and marketization purposes.
Let’s take an extensive look at the new strain on the block.
The Panakeia Hemp Strain – Origins and Properties
Originally developed in a joint collaboration between the Spanish marijuana company Hemp Trading and the Polytechnic University of Valencia (UPV), Panakeia is slowly becoming a considerable alternative to the usual Indica and Sativa strains found in the hemp-based products available to US patients.
Oglesby Plants International, a Florida-based plant nursery, is the US’ biggest producer of the THC-free cannabis plant. Florida A&M University approved the strain under an Industrial Hemp Pilot Project. Currently, the Florida Department of Agriculture and Consumer Services oversees the project’s application.
Scientifically known as “HURV19PAN”, Panaekia is a hemp variation that presents no psychoactive effects whatsoever. With no Delta-8 or Delta-9 THC, and with a significant concentration of cannabigerol (CBG), Panakeia can have remarkable commercial value.
Let’s explore the science of CBG and why it makes Panakeia such a momentous addition to the cannabis product market.
What is CBG?
CBG is the decarboxylated form of cannabigerol acid (CBGA), the parent molecule from which other cannabinoids are synthesized. Just like CBD, it affects the endocannabinoid receptors in our brains and provides therapeutic benefits without the “high” of THC.
Due to a lack of extensive research, all the health benefits of CBG have not yet been fully explored. However, the existing medical studies on CBG show a lot of potential for its use as alternative medicine.
Since they’re both endocannabinoids, the illnesses that benefit from CBD treatment could just as well benefit from CBG medication. These include:
- Anxiety and Depression
- Cachexia (Wasting Syndrome)
- Chronic Pain
- Inflammatory Bowel Diseases (such as Crohn’s Disease and Ulcerative Colitis)
- Various forms of Cancer
Panakeia and Its Impact on the Future of Cannabis
Until the development of Panakeia, CBG was found only in residual amounts inside the marijuana plant. This is because, in the case of most strains, CBG is one of the hardest compounds to extract from a fully matured cannabis plant.
Only found in a 1% quantity, as opposed to the 25-30% abundance of THC and CBD, it previously proved an expensive and inaccessible cannabinoid. But, that all changed with Panakeia.
Panakeia presents a whopping 18% CBG chemical composition. And since it’s equal-parts THC-free and one of the easiest marijuana strains to cultivate, it can easily become the solution to most of the US marijuana market’s current problems.
No THC means never failing a field compliance test due to an unruly plant exceeding the 0.3% compound limit. It means easy transportation without the risk of legal infringement. More than that, it means processing the flower into ready-to-sell products without the need for any THC remediation. Every part of the process gets simplified.
A Milestone Moment for the US Marijuana Industry
Bazalet’s increased production of the Panekeia strain indicates a couple of things:
- New CBD products from the plant are likely to flood the US marijuana market with an even better value proposition.
- The CBG compounds can easily create a wide range of products – including cosmetics, foods, and nutraceuticals.
The continued legalization across the US and many other countries around the globe spell good news all around. They have given cultivators the freedom to develop new strains with distinctive properties, just like Panakeia. These innovations show us that there is much more to cannabis than just CBD and THC, and that we should keep our eyes open to the constant changes that are happening in the world of marijuana.
At the end of the day, Panakeia is the hemp strain that has the best chance to eliminate the current legal obstacles of the medical cannabis market. Simultaneously, its CBG-focused formula can be just as effective as the options that are already available on the market.
In a year of continuous growth for the US marijuana industry, Panakeia brings us together in a CBG-based union. More than that, it gives us an opportunity to finally end the CBD/THC division that has ruled the marijuana market for so long.